BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 11228210)

  • 1. Lipoprotein(a) changes during natural menstrual cycle and ovarian stimulation with recombinant and highly purified urinary FSH.
    Ricci G; Tamaro G; Simeone R; Giolo E; Nucera G; De Seta F; Guaschino S
    Hum Reprod; 2001 Mar; 16(3):449-56. PubMed ID: 11228210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of highly purified urinary FSH and recombinant FSH on haemostasis: an open-label, randomized, controlled trial.
    Ricci G; Cerneca F; Simeone R; Pozzobon C; Guarnieri S; Sartore A; Pregazzi R; Guaschino S
    Hum Reprod; 2004 Apr; 19(4):838-48. PubMed ID: 15016779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist.
    Ragni G; Vegetti W; Baroni E; Colombo M; Arnoldi M; Lombroso G; Crosignani PG
    Hum Reprod; 2001 Nov; 16(11):2258-62. PubMed ID: 11679500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F) versus highly purified urinary FSH (Metrodin HP): results of a randomized comparative study in women undergoing assisted reproductive techniques.
    Bergh C; Howles CM; Borg K; Hamberger L; Josefsson B; Nilsson L; Wikland M
    Hum Reprod; 1997 Oct; 12(10):2133-9. PubMed ID: 9402268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A double-blind, randomized study to compare recombinant human follicle stimulating hormone (FSH; Gonal-F) with highly purified urinary FSH (Metrodin) HP) in women undergoing assisted reproductive techniques including intracytoplasmic sperm injection. The French Multicentre Trialists.
    Frydman R; Howles CM; Truong F
    Hum Reprod; 2000 Mar; 15(3):520-5. PubMed ID: 10686190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
    Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of different gonadotropin combinations to support ovulation induction in WHO type I anovulation infertility: clinical evidences of human recombinant FSH/human recombinant LH in a 2:1 ratio and highly purified human menopausal gonadotropin stimulation protocols.
    Carone D; Caropreso C; Vitti A; Chiappetta R
    J Endocrinol Invest; 2012 Dec; 35(11):996-1002. PubMed ID: 23095369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luteinizing hormone response to gonadotrophin-releasing hormone in normal women undergoing ovulation induction with urinary or recombinant follicle stimulating hormone.
    Messinis IE; Milingos S; Zikopoulos K; Hasiotis G; Seferiadis K; Lolis D
    Hum Reprod; 1998 Sep; 13(9):2415-20. PubMed ID: 9806260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of LH and FSH in ovarian function.
    Howles CM
    Mol Cell Endocrinol; 2000 Mar; 161(1-2):25-30. PubMed ID: 10773387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral and not central suppression of ovarian function during osmotic pump infusion of adrenocorticotropin-(1-24) for one menstrual cycle in the cynomolgus monkey and its partial compensation by a transitory elevation of sex hormone-binding globulin levels.
    Kowalski W; Chatterton RT
    Endocrinology; 1992 Jun; 130(6):3582-92. PubMed ID: 1597155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression of LH during ovarian stimulation: effects differ in cycles stimulated with purified urinary FSH and recombinant FSH.
    Fleming R; Rehka P; Deshpande N; Jamieson ME; Yates RW; Lyall H
    Hum Reprod; 2000 Jul; 15(7):1440-5. PubMed ID: 10875848
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
    Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
    Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human inhibin-A administered early in the menstrual cycle alters concurrent pituitary and follicular, plus subsequent luteal, function in rhesus monkeys.
    Molskness TA; Woodruff TK; Hess DL; Dahl KD; Stouffer RL
    J Clin Endocrinol Metab; 1996 Nov; 81(11):4002-6. PubMed ID: 8923851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of mifepristone (RU486) on the pituitary response to gonadotrophin releasing hormone in women.
    Kazem R; Messinis LE; Fowler P; Groome NP; Knight PG; Templeton AA
    Hum Reprod; 1996 Dec; 11(12):2585-90. PubMed ID: 9021355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU).
    Gerris J; De Vits A; Joostens M; Van Royen E
    Hum Reprod; 1995 Jan; 10(1):56-62. PubMed ID: 7745071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of follicular growth and production of a normal hormonal milieu in spite of using a constant low dose of luteinizing hormone in women with hypogonadotrophic hypogonadism.
    Shoham Z; Howles CM; Zalel Y; Weissman A; Insler V
    Hum Reprod; 1994 Mar; 9(3):431-6. PubMed ID: 7516348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Involvement of ovarian factors magnified by pharmacological induction of multiple follicular development (MFD) in the increase in Ca125 occurring during the luteal phase and the first 12 weeks of induced pregnancies.
    Paoletti AM; Serra GG; Mais V; Ajossa S; Guerriero S; OrrĂ¹ M; Melis GB
    J Assist Reprod Genet; 1995 Apr; 12(4):263-8. PubMed ID: 7580023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomized study.
    Erdem A; Erdem M; Atmaca S; Guler I
    Fertil Steril; 2009 Jun; 91(6):2508-13. PubMed ID: 18692788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroid receptor expression in late follicular phase endometrium in GnRH antagonist IVF cycles is already altered, indicating initiation of early luteal phase transformation in the absence of secretory changes.
    Papanikolaou EG; Bourgain C; Kolibianakis E; Tournaye H; Devroey P
    Hum Reprod; 2005 Jun; 20(6):1541-7. PubMed ID: 15705618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.